GOLDEN, Colo.--(BUSINESS WIRE)--Vitro Diagnostics, Inc. (OTCBB: VODG)(OTCQB: VODG), dba Vitro Biopharma, announced that it signed an amendment to its contract to jointly manufacture and distribute stem cell analysis tools with HemoGenix®, Inc., a leading firm known for its pioneering HALO® analysis platform for stem cells. The previous agreement with HemoGenix® led to the launch of LUMENESC-Hu™ & LumiSTEM™ assays for high performance analysis of certain types of adult stem cells. The new amendment expands the original agreement to include development of stem cell culture media and high performance toxicity assays to provide new cell-based tools for drug discovery and development. The partners also agreed to align their respective quality programs to assure consistency.
